摘要
目的观察舒肝明目汤治疗青光眼睫状体炎综合征(PSS)的临床疗效。方法收集2017年2月—2018年1月于遂宁市第一人民医院眼科诊断为肝肾亏虚型PSS患者80例,按随机数字表法分为观察组和对照组各40例。对照组采用妥布霉素地塞米松滴眼液和马来酸噻吗洛尔滴眼液治疗,观察组在此基础上口服舒肝明目汤,2组均治疗30 d,并随访2年。比较2组治疗前后视力、眼压、角膜后沉着物(KP)数目、血清炎症因子水平、症状评分及复发情况。结果(1)有效率:治疗后,观察组总有效率为87.50%,高于对照组的65.00%,2组比较差异有统计学意义(χ^2=4.501,P=0.034)。(2)视力、眼压、KP数及症状积分:治疗后组间比较,观察组视力(t=4.300,P=0.000)、眼压(t=7.653,P=0.000)、KP数目(t=29.093,P=0.000)、症状积分(t=8.752,P=0.000)均优于对照组,差异有统计学意义。治疗前后比较,观察组视力(t=4.829,P=0.000)、眼压(t=4.392,P=0.000)、KP数目(t=27.563,P=0.000)、症状积分(t=7.382,P=0.000);对照组视力(t=5.441,P=0.000)、眼压(t=5.382,P=0.000)、KP数目(t=25.018,P=0.000)、症状积分(t=7.326,P=0.000),差异均有统计学意义。(3)血清炎症因子水平:治疗后组间比较,IL-4(t=4.734,P=0.000)、IFN-γ(t=3.745,P=0.000),差异均有统计学意义。治疗前后比较,观察组IL-4(t=5.383,P=0.000)、IFN-γ(t=4.762,P=0.000),对照组IL-4(t=7.382,P=0.000)、IFN-γ(t=4.985,P=0.000),差异有统计学意义。(4)复发率:2组复发情况比较,其中观察组≤3次复发率(12.50%)低于对照组(37.50%),差异有统计学意义(χ^2=6.667,P=0.010)。观察组复发在4~7次复发率(12.50%)低于对照组(32.50%),差异有统计学意义(χ^2=4.588,P=0.032)。结论口服舒肝明目汤可改善PSS患者的视力、眼压及KP数目,可有效调节血清炎症因子水平,缓解临床症状,降低复发率,且优于对照组。
OBJECTIVE To investigate the clinical efficacy of Shugan Mingmu decoction in treatment of posner-schlossman syndrome(PSS).METHODS From February 2017 to January 2018,according to the random number table,80 PSS patients with liver depression and spleen deficiency were divided into observation group and control group with 40 cases each.The control group was treated with dexamethasone eye drops and timolol eye drops.On the basis of the above,the observation group was treated with Shugan Mingmu decoction.Both groups were treated for 30 days,and followed up for 2 year.The visual acuity,intraocular pressure,number of posterior corneal deposits(KP),serum inflammatory factors levels,symptom scores and recurrence rate were compared between the two groups.RESULTS(1)Effective rate:after treatment,the total effective rate of the observation group(87.50%),was higher than that of the control group(65.00%).The difference between the two groups was statistically significant(χ^2=4.501,P=0.034).(2)Visual acuity,intraocular pressure,KP number and symptom score:After treatment,visual acuity(t=4.300,P=0.000),intraocular pressure(t=7.653,P=0.000),KP number(t=29.093,P=0.000)and symptom score(t=8.752,P=0.000)in the observation group were better than that of the control group,and the differences were statistically significant.Comparison before and after treatment:visual acuity(t=4.829,P=0.000),intraocular pressure(t=4.392,P=0.000),KP number(t=27.563,P=0.000),symptom score(t=7.382,P=0.000)in the observation group were better than that of the control group which were the visual acuity of the control group(t=5.441,P=0.000),intraocular pressure(t=5.382,P=0.000),KP number(t=25.018,P=0.000),symptom score(t=7.326,P=0.000),and the difference is statistically significant.(3)Serum inflammatory factor levels:Comparing the groups after treatment,IL-4(t=4.734,P=0.000)and IFN-γ(t=3.745,P=0.000)of the observation group were better than those of the control group,and the difference was statistically significant.Before and after treatment,IL-4(t=5.383,P=0.000),IFN-γ(t=4.762,P=0.000)in the observation group,IL-4(t=7.382,P=0.000),IFN-γin the control group(t=4.985,P=0.000),the difference is statistically significant.(4)Recurrence rate:comparing the recurrence of the two groups,the recurrence rate less than 4 times(12.50%)in the observation group was lower than of the control group(37.50%).The difference was statistically significant(χ^2=6.667,P=0.010).The recurrence rate between 4 and 7 times(12.50%)in the observation group was lower than that of the control group(32.50%).The difference was statistically significant(χ^2=4.588,P=0.032).CONCLUSIONS Shugan Mingmu decoction can improve the vision,intraocular pressure,and KP number of PSS patients.It can effectively adjust the level of serum inflammatory factors,relieve clinical symptoms,and reduce the recurrence rate,and is better than the control group.
作者
章沐曦
张伟
周金红
吴海星
黄勤
金涛
ZHANG Muxi;ZHANG Wei;ZHOU Jinhong(Suining First People's Hospital,Suining 629000,China)
出处
《中国中医眼科杂志》
2020年第12期860-864,共5页
China Journal of Chinese Ophthalmology
